Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
atazanavir · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| S1 P1 TDF + DNV/r | EXPERIMENTAL | - |
| S1/S2 P2 DNV/r + ATZ | EXPERIMENTAL | - |
| S2 P1 ATZ/r | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| atazanavir | DRUG | multiple oral doses |
| danoprevir | DRUG | multiple oral doses |
| ritonavir | DRUG | multiple oral doses |
| tenofovir disoproxil fumarate | DRUG | single oral doses |
Inclusion Criteria: * Male and female volunteers, 18 to 55 years of age, inclusive * Body weight \>/= 55 kg * Body mass index (BMI) 18.0 - 32.0 kg/m2 * Healthy non-smoking subjects. Healthy status will be defined by absence of evidence of any active or chronic disease following a detailed medical a...
Atazanavir is a small molecule drug being studied in a Phase 1 clinical trial. It is being investigated in healthy volunteers as part of a drug-drug interaction study. The drug is being developed by Roche Holding AG.
Atazanavir is being studied for use in healthy volunteers in a clinical trial context. The specific trial is a drug-drug interaction study, but the drug itself is not being developed for a particular disease indication in this study.
Atazanavir is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting a Phase 1 clinical trial involving this drug.
Atazanavir is in Phase 1 clinical development. It has one completed trial with 40 participants enrolled. The drug is investigational and has not been approved for any use.
Atazanavir has one completed Phase 1 clinical trial, identified as NCT01592305. This study examined drug-drug interactions between danoprevir coadministered with low-dose ritonavir and tenofovir disoproxil fumarate or atazanavir. The trial was conducted in the United States with 40 healthy volunteers.